Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial

Vivek Verma, Audrey J Lazenby, Dandan Zheng, Abhijeet R. Bhirud, Quan P Ly, Chandrakanth Are, Aaron R. Sasson, Chi Lin

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose Prospectively assess relationships between dosimetric parameters and histopathologic/clinical duodenal toxicities in patients on a phase I trial for pancreatic cancer. Methods Forty-six borderline resectable/unresectable patients were enrolled on a prospective trial testing neoadjuvant gemcitabine/5-fluorouracil followed by SBRT (5 daily fractions of 5–8 Gy) and concurrent nelfinavir. Post-SBRT surgery was performed in 13 resectable patients, which constituted the patient population herein. Pathologic duodenal damage was assessed using predetermined criteria: 1, no/minimal; 2, moderate; and 3, marked damage. Clinical toxicities were assessed per the Clinical Terminology Criteria for Adverse Events (CTCAE). Duodenal dosimetric parameters included V5–V40 and mean/maximum doses. Spearman correlation and linear regression evaluated associations between dosimetric parameters and clinical/pathologic duodenal toxicity. Results The median duodenal mean and maximum doses were 20 and 37 Gy. Median duodenal V5–V40 were 64, 62, 52, 39, 27, 14, 5 and 0 cc, respectively. The median duodenal damage score was 2 (four 1, eight 2, and one 3). Higher duodenal damage scores correlated with higher duodenal mean doses (r = 0.75, p = 0.003), V35 (r = 0.61, p = 0.03), V30 (r = 0.67, p = 0.01), V25 (r = 0.68, p = 0.01), V20 (r = 0.56, p = 0.05), and the planning target volume (PTV) mean (r = 0.59, p = 0.03) and maximum (r = 0.61, p = 0.03) doses. Clinical toxicities did not correlate with dosimetric parameters or duodenal pathologic damage. Conclusions Duodenal histologic damage correlates with mean duodenal dose, V20-V35, and PTV mean/maximum doses.

Original languageEnglish (US)
Pages (from-to)464-469
Number of pages6
JournalRadiotherapy and Oncology
Volume122
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Radiosurgery
Pancreatic Neoplasms
Clinical Trials
gemcitabine
Nelfinavir
Terminology
Fluorouracil
Linear Models
Population

Keywords

  • Duodenum
  • Pancreatic cancer
  • Stereotactic body radiotherapy
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{41a8b862e95b4b0a8ae496b1b4dfcc2c,
title = "Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial",
abstract = "Purpose Prospectively assess relationships between dosimetric parameters and histopathologic/clinical duodenal toxicities in patients on a phase I trial for pancreatic cancer. Methods Forty-six borderline resectable/unresectable patients were enrolled on a prospective trial testing neoadjuvant gemcitabine/5-fluorouracil followed by SBRT (5 daily fractions of 5–8 Gy) and concurrent nelfinavir. Post-SBRT surgery was performed in 13 resectable patients, which constituted the patient population herein. Pathologic duodenal damage was assessed using predetermined criteria: 1, no/minimal; 2, moderate; and 3, marked damage. Clinical toxicities were assessed per the Clinical Terminology Criteria for Adverse Events (CTCAE). Duodenal dosimetric parameters included V5–V40 and mean/maximum doses. Spearman correlation and linear regression evaluated associations between dosimetric parameters and clinical/pathologic duodenal toxicity. Results The median duodenal mean and maximum doses were 20 and 37 Gy. Median duodenal V5–V40 were 64, 62, 52, 39, 27, 14, 5 and 0 cc, respectively. The median duodenal damage score was 2 (four 1, eight 2, and one 3). Higher duodenal damage scores correlated with higher duodenal mean doses (r = 0.75, p = 0.003), V35 (r = 0.61, p = 0.03), V30 (r = 0.67, p = 0.01), V25 (r = 0.68, p = 0.01), V20 (r = 0.56, p = 0.05), and the planning target volume (PTV) mean (r = 0.59, p = 0.03) and maximum (r = 0.61, p = 0.03) doses. Clinical toxicities did not correlate with dosimetric parameters or duodenal pathologic damage. Conclusions Duodenal histologic damage correlates with mean duodenal dose, V20-V35, and PTV mean/maximum doses.",
keywords = "Duodenum, Pancreatic cancer, Stereotactic body radiotherapy, Toxicity",
author = "Vivek Verma and Lazenby, {Audrey J} and Dandan Zheng and Bhirud, {Abhijeet R.} and Ly, {Quan P} and Chandrakanth Are and Sasson, {Aaron R.} and Chi Lin",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.radonc.2016.12.030",
language = "English (US)",
volume = "122",
pages = "464--469",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer

T2 - Secondary analysis of a prospective clinical trial

AU - Verma, Vivek

AU - Lazenby, Audrey J

AU - Zheng, Dandan

AU - Bhirud, Abhijeet R.

AU - Ly, Quan P

AU - Are, Chandrakanth

AU - Sasson, Aaron R.

AU - Lin, Chi

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Purpose Prospectively assess relationships between dosimetric parameters and histopathologic/clinical duodenal toxicities in patients on a phase I trial for pancreatic cancer. Methods Forty-six borderline resectable/unresectable patients were enrolled on a prospective trial testing neoadjuvant gemcitabine/5-fluorouracil followed by SBRT (5 daily fractions of 5–8 Gy) and concurrent nelfinavir. Post-SBRT surgery was performed in 13 resectable patients, which constituted the patient population herein. Pathologic duodenal damage was assessed using predetermined criteria: 1, no/minimal; 2, moderate; and 3, marked damage. Clinical toxicities were assessed per the Clinical Terminology Criteria for Adverse Events (CTCAE). Duodenal dosimetric parameters included V5–V40 and mean/maximum doses. Spearman correlation and linear regression evaluated associations between dosimetric parameters and clinical/pathologic duodenal toxicity. Results The median duodenal mean and maximum doses were 20 and 37 Gy. Median duodenal V5–V40 were 64, 62, 52, 39, 27, 14, 5 and 0 cc, respectively. The median duodenal damage score was 2 (four 1, eight 2, and one 3). Higher duodenal damage scores correlated with higher duodenal mean doses (r = 0.75, p = 0.003), V35 (r = 0.61, p = 0.03), V30 (r = 0.67, p = 0.01), V25 (r = 0.68, p = 0.01), V20 (r = 0.56, p = 0.05), and the planning target volume (PTV) mean (r = 0.59, p = 0.03) and maximum (r = 0.61, p = 0.03) doses. Clinical toxicities did not correlate with dosimetric parameters or duodenal pathologic damage. Conclusions Duodenal histologic damage correlates with mean duodenal dose, V20-V35, and PTV mean/maximum doses.

AB - Purpose Prospectively assess relationships between dosimetric parameters and histopathologic/clinical duodenal toxicities in patients on a phase I trial for pancreatic cancer. Methods Forty-six borderline resectable/unresectable patients were enrolled on a prospective trial testing neoadjuvant gemcitabine/5-fluorouracil followed by SBRT (5 daily fractions of 5–8 Gy) and concurrent nelfinavir. Post-SBRT surgery was performed in 13 resectable patients, which constituted the patient population herein. Pathologic duodenal damage was assessed using predetermined criteria: 1, no/minimal; 2, moderate; and 3, marked damage. Clinical toxicities were assessed per the Clinical Terminology Criteria for Adverse Events (CTCAE). Duodenal dosimetric parameters included V5–V40 and mean/maximum doses. Spearman correlation and linear regression evaluated associations between dosimetric parameters and clinical/pathologic duodenal toxicity. Results The median duodenal mean and maximum doses were 20 and 37 Gy. Median duodenal V5–V40 were 64, 62, 52, 39, 27, 14, 5 and 0 cc, respectively. The median duodenal damage score was 2 (four 1, eight 2, and one 3). Higher duodenal damage scores correlated with higher duodenal mean doses (r = 0.75, p = 0.003), V35 (r = 0.61, p = 0.03), V30 (r = 0.67, p = 0.01), V25 (r = 0.68, p = 0.01), V20 (r = 0.56, p = 0.05), and the planning target volume (PTV) mean (r = 0.59, p = 0.03) and maximum (r = 0.61, p = 0.03) doses. Clinical toxicities did not correlate with dosimetric parameters or duodenal pathologic damage. Conclusions Duodenal histologic damage correlates with mean duodenal dose, V20-V35, and PTV mean/maximum doses.

KW - Duodenum

KW - Pancreatic cancer

KW - Stereotactic body radiotherapy

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85009508344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009508344&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2016.12.030

DO - 10.1016/j.radonc.2016.12.030

M3 - Article

C2 - 28089484

AN - SCOPUS:85009508344

VL - 122

SP - 464

EP - 469

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 3

ER -